Critical Analysis: Mural Oncology (MURA) & Its Peers

Mural Oncology (NASDAQ:MURA) is one of 1,049 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Mural Oncology to related businesses based on the strength of its analyst recommendations, valuation, profitability, dividends, institutional ownership, earnings and risk.

Profitability

This table compares Mural Oncology and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mural Oncology	N/A	-70.10%	-61.30%
Mural Oncology Competitors	-3,610.16%	-274.38%	-39.07%

Insider & Institutional Ownership

80.2% of Mural Oncology shares are owned by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 0.1% of Mural Oncology shares are owned by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Mural Oncology and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mural Oncology	0	0	3	1	3.25
Mural Oncology Competitors	7622	20910	48555	1193	2.55

Mural Oncology currently has a consensus price target of $16.00, suggesting a potential upside of 307.12%. As a group, “Pharmaceutical preparations” companies have a potential upside of 71.10%. Given Mural Oncology’s stronger consensus rating and higher probable upside, equities analysts plainly believe Mural Oncology is more favorable than its rivals.

Valuation & Earnings

This table compares Mural Oncology and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mural Oncology	N/A	-$207.45 million	-0.43
Mural Oncology Competitors	$1.72 billion	$154.00 million	-5.60

Mural Oncology’s rivals have higher revenue and earnings than Mural Oncology. Mural Oncology is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Mural Oncology beats its rivals on 8 of the 12 factors compared.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.